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Tumor endothelial marker 1 (TEM1; also known as endosialin or CD248) is a protein found on tumor vas-
culature and in tumor stroma. Here, we tested whether TEM1 has potential as a therapeutic target for cancer 
immunotherapy by immunizing immunocompetent mice with Tem1 cDNA fused to the minimal domain of 
the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine). Tem1-TT vaccination elicited CD8+ 
and/or CD4+ T cell responses against immunodominant TEM1 protein sequences. Prophylactic immunization 
of animals with Tem1-TT prevented or delayed tumor formation in several murine tumor models. Therapeutic 
vaccination of tumor-bearing mice reduced tumor vascularity, increased infiltration of CD3+ T cells into the 
tumor, and controlled progression of established tumors. Tem1-TT vaccination also elicited CD8+ cytotoxic T 
cell responses against murine tumor-specific antigens. Effective Tem1-TT vaccination did not affect angiogen-
esis-dependent physiological processes, including wound healing and reproduction. Based on these data and 
the widespread expression of TEM1 on the vasculature of different tumor types, we conclude that targeting 
TEM1 has therapeutic potential in cancer immunotherapy.
Introduction
Angiogenesis, the growth of new blood vessels from preexisting 
vessels, is essential for many physiological processes, such as preg-
nancy, embryonic development, and wound healing (1). However, 
uncontrolled or defective angiogenesis also contributes to many 
pathological processes, including tumor growth and metastasis (2).
Targeting angiogenesis is a promising strategy for the treat-
ment of cancer. Tumor-associated blood vessels differ from vessels 
of normal tissue both structurally and functionally and can offer 
unique molecular targets for therapeutic interventions (3–5). There 
are several advantages to targeting the vasculature rather than the 
tumor cells proper. Tumor-associated vascular antigens are broadly 
expressed on cancers of different histological types, whereas they 
are generally absent or poorly expressed on most normal tissues 
(6–8). Immunotherapy may also elicit a significant bystander effect, 
because each capillary is thought to support hundreds of tumor 
cells and adaptive or antibody-mediated immune responses can eas-
ily access the tumor vasculature, whereas tumor islets may be com-
partmentalized and less accessible. Also, adaptive immunotherapy 
can persist, leaving a long-lasting memory response that protects 
the host against tumor recurrence. Finally, tumor cells are intrinsi-
cally more genetically unstable than vascular endothelial cells, and 
targeting them directly may promote tumor escape mechanisms (9).
Plasmid DNA offers a safe and promising method for vaccina-
tion and is approved for cancer immunotherapy for veterinary use 
(10). However, the immune responses induced to date by DNA vac-
cines in humans have been relatively weak compared with conven-
tional vaccines, an issue that is particularly relevant for cancer vac-
cines because of the limited immunogenicity of tumor antigens. 
A combination of approaches are being studied to boost immune 
responses. In vivo electroporation of plasmid DNA or electrogene 
transfer increases DNA uptake, leading to enhanced expression in 
treated muscle and a concomitant increase in immune responses 
to the target antigen (11). The minimized domain of the C frag-
ment of tetanus toxoid (TT) has been used to elicit antigen-specif-
ic immune responses (12). For example, DNA vectors encoding the 
tumor-associated antigen carcinoembryonic antigen (CEA) fused 
to TT can break tolerance to CEA and elicit significant antigen-
specific CD8+ T cell–mediated immune responses (13).
Human tumor endothelial marker 1 (TEM1; also known as 
endosialin or CD248) is overexpressed in the vasculature of carci-
nomas and brain tumors as well as in the vasculature and stroma 
of most sarcomas (14–17). Expression of TEM1 is variable among 
tumor types; it may be expressed on endothelial cells, pericytes, 
and fibroblasts in both mouse tumors (18) and human tumors 
(19, 20). Human TEM1 gene expression is also induced by hypox-
ia under the regulation of HIF-2α (21). In the mouse, TEM1 is 
overexpressed during embryonic development, but is largely 
absent in adult tissue (18, 22). TEM1 is one of the most abun-
dantly expressed tumor endothelial or stromal antigens in human 
tumors, making it a prime candidate for immunological targeting.
We hypothesized that effective DNA vaccination using TT as 
an adjuvant would be able to break tolerance to TEM1 and gen-
erate adaptive immunity targeted to the tumor vasculature. We 
propose that such vaccination can elicit potent antitumor activity 
in TEM1-expressing tumors by ablation of the tumor vasculature 
without affecting normal physiological functions that are depen-
dent on angiogenesis. We tested these hypotheses by genetically 
fusing mouse Tem1 cDNA with the first domain of fragment C of 
TT, creating a DNA vaccine (referred to herein as Tem1-TT) that 
we administered i.m. via electrogene transfer.
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Results
DNA vaccination with Tem1-TT breaks tolerance to TEM1. Consistent 
with previous work in humans and mice, we found that Tem1 was 
overexpressed in actively growing tumors of different background 
or histology (TC1, CT26, and LLC models) and was expressed at very 
low to undetectable levels in mouse normal tissues, as quantified by 
quantitative RT-PCR (qRT-PCR; Figure 1A and data not shown). In 
the hypervascularized CT26 mouse colon carcinoma model, Tem1 
mRNA was found to localize with, or to be in close juxtaposition 
to, CD31 mRNA (Figure 1B and Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI67382DS1), which suggests that TEM1 is expressed by ECs 
and/or pericytes. These findings support the notion that TEM1 
is an overexpressed vasculature-associated antigen in CT26 colon 
tumors, which can serve as a target for antitumor vascular therapy.
Using pcDNA3.1 as a DNA plasmid vector, the Tem1 gene 
sequence was fused to the first domain of the C fragment of the TT 
sequence (TT 865–1,120) at its carboxyl terminal (see Methods). 
Expression levels of both sequences were measured by qRT-PCR 
after transient transfection of CHO cells (Figure 1C). This fusion 
construct was used to vaccinate healthy mice at 1-week intervals for 
a total of 3 immunizations. Splenocytes harvested from vaccinated 
mice were stimulated with a TEM1 peptide library consisting of 15 
mers that overlap by 10 aa. The TEM1 library encompassing the 
entire protein sequence was divided into 4 pools: pool A (sequenc-
es spanning aa 1–197), pool B (aa 187–377), pool C (aa 367–557), 
and pool D (aa 547–765). This peptide-based approach facili-
tates the detection of CD8+ and CD4+ T cells that are specific for 
TEM1 sequences in the context of MHC class I and MHC class II, 
respectively (23). IFN-γ enzyme-linked immunosorbent spot 
assay (ELISpot) and intracellular staining (ICS) indicated that the 
majority of CD8+ and CD4+ T cell epitopes in BALB/c mice were 
contained within pool C (Figure 2A). Spleen-derived CD8+ T cells 
from vaccinated C57BL/6 mice exhibited reactivity against pool 
D, whereas CD4+ T cell responses were not detected (Figure 2B). 
As hypothesized, only the Tem1-TT DNA fusion vaccine was able 
to break tolerance to TEM1; specific responses were not detected 
in mice of either strain that were vaccinated with DNA encoding 
Tem1 or TT adjuvant alone.
To characterize the TEM1 sequences recognized by CD4+ and 
CD8+ T cells generated by the Tem1-TT vaccine, pools C and D 
were deconvoluted using a matrix scheme. For the BALB/c strain, 
pool C was further divided into minipools. TEM1-specific reac-
tivity was found against minipools f, g, and 5 (Figure 2C). IFN-γ 
ICS analysis revealed that minipools g and 5, corresponding to 
TEM1516–530 (ITSATHPARSPPYQP), induced a stronger CD8+ T 
cell response compared with minipools f and 5, corresponding 
to TEM1511–525 (GHKPGITSATHPARS). Both TEM1516–530 and 
Figure 1
Physiological and plasmid DNA-induced TEM1 expression. (A) Tem1 was expressed in tumors in vivo. qRT-PCR was performed with a Tem1 probe. 
An 18S probe was used as an endogenous control, and samples were normalized with mouse liver. Post–qRT-PCR calculations to analyze relative 
gene expression were performed by the 2−ΔΔCt method. Error bars denote SD (n = 5). (B) Tem1 RNA colocalized with CD31+ cells. CT26 tumor sec-
tions were subjected to immunofluorescence with a CD31 antibody (red) and single-molecule RNA FISH for Tem1 (yellow) or CD31 (cyan). Bright 
spots in the RNA FISH channels correspond to individual transcript molecules. DAPI staining (purple) shows cell nuclei. Original magnification, 
×100. Images shown are 85 μm wide. (C) Expression of the Tem1-TT DNA plasmid. A fusion Tem1-TT construct was generated by fusing codon-
optimized Tem1 cDNA (nt 1–2,297; aa 1–765) with the cDNA of the amino terminal domain of the fragment C of TT (819 bp, 273 aa). Expression 
of Tem1 or TT after transfection of the Tem1-TT construct was tested with CHO cells and assessed by qRT-PCR. Error bars denote SD (n = 3).
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TEM1511–525 peptides stimulated a CD4+ T cell response (data 
not shown). We therefore decided to use the TEM1516–530 peptide 
for subsequent monitoring of the immune response in BALB/c 
mice. Using the same approach to further divide pool D into 
minipools for testing the C57BL/6 background, a specific TEM1 
response was detected for minipools a and 6, corresponding to 
the TEM1696–710 peptide (GQSQRDDRWLLVALL) (Figure 2D). 
Using IFN-γ ICS, this sequence was found to specifically acti-
vate CD8+ T cells (data not shown), which indicates that peptide 
TEM1696–710 contains the immunodominant CD8+ T cell epitope 
for C57BL/6 mice.
To confirm that the TEM1696–710 peptide mediates target cell 
recognition and killing by CTL, splenocytes from vaccinated 
C57BL/6 mice were harvested and tested in mixed leukocyte 
peptide–stimulated culture (MLPC). MBL2 leukemia cells were 
used as the stimulatory cells. MLPCs were pulsed with TEM1696–710 
or control peptides for 5 days and tested for IFN-γ secretion 
by ELISA and in a 51Cr cytotoxicity CTL assay. IFN-γ ELISA 
revealed that Tem1-TT vaccination selectively generated anti-
gen-specific T cells that recognize the TEM1696–710 peptide, but 
not the control peptides TEM1691–705 or β-gal96–103 (Figure 2E). 
Splenocytes from vaccinated C57BL/6 mice were also able to rec-
Figure 2
Characterization of TEM1 immunodominant epitopes. (A and B) Specific peptide pools restricted in H-2d (A) and H-2b (B) haplotypes. 1 × 106 
splenocytes from BALB/c (A) or C57BL/6 (B) mice vaccinated with Tem1-TT were cultured with the 4 TEM1 peptide pools and tested by ELISpot 
and ICS for IFN-γ secretion. (A) Splenocytes from Tem1-TT–vaccinated BALB/c mice recognized pool C (left), which induced CD3+CD4+ (middle) 
and CD3+CD8+ (right) T cell responses. (B) Splenocytes from Tem1-TT–vaccinated C57BL/6 mice recognized pool D (left). By ICS, there was a 
specific CD3+CD8+ response (right). Data are mean ± SD (n = 5 per group) from 1 of 3 experiments. (C and D) Characterization of TEM1-derived 
peptides specific for H-2d (C) and H-2b (D) haplotypes. Peptides from pool C (C) or pool D (D) were divided into 7 minipools of 15 mers, so each 
individual peptide was present in 2 minipools and could be identified through an experimental matrix design. (C) Reactivity to pool C was present 
in minipools f, g, and 5. (D) Reactivity to pool D was present in minipools a and 6. Data are from 1 of 3 independent experiments. (E) TEM1696–710 
induced IFN-γ secretion and cytotoxic effector activity. Splenocytes from TT-, Tem1-, or Tem1-TT–vaccinated mice was used in peptide-stimulated 
cultures and tested in an IFN-γ secretion ELISA (left) and CTL assay (right). Tem1-TT exclusively primed and expanded antigen-specific CD8+ T 
cells that killed ECs in the context of MHC class I/TEM1696–710 peptide, but not control peptides.
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ognize unpulsed or TEM1696–710–pulsed H5V ECs, which express 
endogenous TEM1 protein, whereas MS1 ECs (which do not 
express TEM1; ref. 24) required TEM1 peptide pulsing to stim-
ulate splenocytes from Tem1-TT–vaccinated mice (Figure 2E). 
In CTL assays, splenocytes from Tem1-TT–vaccinated mice 
efficiently lysed all 3 target cell types when pulsed with TEM1 
peptide (Figure 2E). Together, these data suggest that Tem1-TT 
can break tolerance and elicit functional CD8+ T cells that are 
specific for TEM1 epitopes. Furthermore, ECs can naturally pro-
cess the endogenous TEM1 antigen and are able to present the 
cognate TEM1 peptide in an MHC class I–restricted fashion.
Tem1-TT DNA vaccine suppresses tumor growth and induces CD3+ T 
cell tumor infiltration. To evaluate the ability of Tem1-TT vaccina-
tion to control tumor growth in vivo, we tested both prophylactic 
and therapeutic vaccine approaches using CT26, TC1, and LLC 
tumor models. Mice were vaccinated 3 times i.m. at weekly inter-
vals, followed by tumor challenge (prophylactic), or tumor cells 
were inoculated first and then 3–5 days later were given 3 weekly 
Figure 3
Tem1-TT vaccination controls tumor progression. (A) Tumor control in a prophylactic setting. BALB/c and C57BL/6 mice were immunized 3 times 
with Tem1, TT, or Tem1-TT vaccines, then injected s.c. with 1 × 105 CT26, TC1, or LLC cells. Data are mean ± SD (n = 10 per group) from 1 of 
5 experiments. P < 0.05, Tem1-TT vs. Tem1 and Tem1-TT vs. TT (CT26, TC1, and LLC), pairwise multiple-comparison Tukey test. (B and C) Inhibi-
tion of CT26 and TC1 tumor progression and induction of CD3+ T cell infiltration in a therapeutic setting. BALB/c mice were injected s.c. with 1 × 105 
CT26 cells (B), and C57BL/6 mice were injected with 1 × 105 TC1 cells (C). Mice were immunized 1 day, 1 week, and 2 weeks later with Tem1, 
TT, or Tem1-TT vaccine and euthanized 33 (B) or 29 (C) days after tumor challenge. Left: Data points are mean ± SD (n = 10 mice/group) from 1 
of 3 experiments. P < 0.05, Tem1-TT vs. Tem1 and Tem1-TT vs. TT (CT26 and TC1), Tukey test. CD3+ T cells in corresponding tumor sections and 
quantification are also shown. Original magnification, ×20. Data are mean ± SD of a representative experiment (n = 5 per group).
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vaccinations (therapeutic). Prophylactic treatment with Tem1-
TT induced significant tumor protection compared with single 
Tem1 and TT constructs in all 3 tumor models (Figure 3A). 
These results reinforced the notion that the fusion construct 
Tem1-TT vaccine is essential to break TEM1 tolerance and gen-
erate protective immunity.
Therapeutic Tem1-TT vaccination conferred significant tumor 
protection compared with single construct controls in CT26 and 
TC1 tumor-bearing mice (Figure 3, B and C). Analysis of CD3+ T 
cell tumor infiltration by immunohistochemistry revealed consis-
tent, heavy infiltration of CD3+ T cells after therapeutic vaccina-
tion with Tem1-TT within CT26 (42 ± 5 CD3+ cells/high-powered 
field [hpf]; P < 0.05 vs. TT) and TC1 tumors (54 ± 11 CD3+ cells/hpf; 
P < 0.05 vs. TT) compared with the single constructs and saline 
control (Figure 3, B and C). Cumulatively, these data indicate that 
the Tem1-TT vaccine induces significant T cell infiltration within 
tumors and exerts potent antitumor activity.
To demonstrate that the antitumor response by Tem1-TT vac-
cine is indeed immune mediated, and to determine whether the 
immune response is cellular or humoral in nature, we performed 
adoptive transfer of CD3+ T cells or sera from Tem1-TT–immu-
nized mice into TC1 tumor-bearing mice (Supplemental Figure 
2). Splenocytes from Tem1-TT–immunized mice were enriched for 
CD3+ cells and inoculated into naive mice. In simultaneous experi-
ments, the serum from immunized mice was also transferred to 
naive mice. Mice were then sublethally irradiated and challenged 
with TC1 tumor. The antitumor response mediated by Tem1-TT 
vaccine was based on the induction of a CD3+ T cell response, where-
as serum had no therapeutic efficacy (Supplemental Figure 2). 
Therefore, although antibodies may be generated by the Tem1-TT 
vaccine, the results of our adoptive transfer experiments ruled out 
any humoral contribution to antitumor efficacy.
Tem1-TT vaccination inhibits tumor vascularization. To determine 
whether Tem1-TT vaccination controls tumor progression by tar-
geting the tumor vasculature, we used common readouts for mea-
suring the effects on the vasculature, but also measured the func-
tional dynamics of the vasculature in the hypervascularized CT26 
model (25). To ensure that tumors of the same size were studied, 
mice that were immunized with Tem1-TT were sacrificed 10 days 
later than mice immunized with TT vaccine, and available tumors 
were harvested. Tumors of similar volume (∼200 mm3) from both 
groups were assessed for tumor hemoglobin levels by ELISA, as a 
readout for blood perfusion. Tumors from mice vaccinated with 
Tem1-TT had significantly decreased hemoglobin levels com-
pared with those of TT-vaccinated mice (Figure 4A), suggestive of 
reduced red blood cell perfusion in these tumors.
Figure 4
Tem1-TT vaccination inhibits CT26 tumor vascularization. (A) Tem1-TT vaccination reduced tumor hemoglobin content. Tumors at approximately 
200 mm3 were excised from TT- or Tem1-TT–vaccinated mice and inspected grossly. Tumors from Tem1-TT–vaccinated mice appeared pale 
relative to control tumors. Reduced hemoglobin levels in tumors from Tem1-TT–vaccinated mice were observed by ELISA. (B) Tem1-TT vaccine 
reduces tumor vascularity. Tumors from TT- or Tem1-TT–vaccinated mice were analyzed by Doppler ultrasound. Perfused tumor area and real 
blood flux are shown, measured and calculated by Doppler image analysis. (C) CT26 tumors from Tem1-TT–immunized mice had significantly 
decreased CD31 expression compared with TT vaccination. Also note the abnormal blood vessel shape. Original magnification, ×20. (D) CAIX 
expression was increased in tumors from Tem1-TT–immunized animals. CAIX expression was visualized by immunohistochemistry, and Caix 
was independently quantified by qRT-PCR in tumors from mice vaccinated with either TT or Tem1-TT. Original magnification, ×20. Data in A–D 
are mean ± SD of a representative experiment (n = 5 per group). Statistical analyses were performed with Student’s t test.
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We then assessed the effects of Tem1-TT vaccination on the func-
tional vasculature by measuring tumor vessel blood perfusion using 
ultrasound for each treatment group when tumors reached ∼600 mm3 
in volume. Gas-filled microbubbles were injected i.v. and acted as 
a contrast agent as they flowed through the tumor blood vessels. 
Regions of perfusion in the tumors were visualized by ultrasound 
pulsing and contrast-enhanced Doppler imaging, which enabled us to 
determine the area of the tumor that was perfused (as a percentage of 
Figure 5
Tem1-TT vaccination induces secondary tumor cell–specific cytotoxic T cell responses in tumor-bearing mice. BALB/c (A) and C57BL/6 (B) mice 
were challenged, vaccinated, and euthanized as in Figure 3, B and C, respectively. 1 × 106 splenocytes from TT-, Tem1-, or Tem1-TT–vaccinated 
mice were tested for their capacity to respond to the specific TEM1 peptide (TEM1516–530), and to AH1 antigen (A) or the TC1 tumor-associated E7 
antigen (B). (A) Tem1-TT–vaccinated splenocytes mounted specific responses against the immunodominant peptide of TEM1 (TEM1516–530) and 
the AH1 antigen, but not control peptide (TEM1506–520), as measured by ELISpot. Tem1-TT induced CD3+CD4+ and CD3+CD8+ T cell responses 
against TEM1 antigen. The CD3+CD8+ T cell response from Tem1-TT–vaccinated mice correlated with suppression of tumor growth. ICS con-
firmed that Tem1-TT immunization induced an AH1-specific CD3+CD8+ T cell response that also correlated with tumor volume. (B) Splenocytes 
from mice vaccinated with Tem1-TT recognized TEM1696–710 peptide and the E7 antigen, but not control peptide (TEM1691–705). Only Tem1-TT vac-
cination was able to induce both a TEM1 and an E7 CD3+CD8+ T cell response, both of which correlated with tumor volume. Correlation analysis 
was performed by Spearman’s rank correlation.
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total tumor area) as well as the red blood cell flux (rate of blood flow) 
per unit area of the tissue (color-weighted fractional area) (26, 27). 
Contrast-enhanced images (after perfusion) showed a marked reduc-
tion in tumor perfusion (colored regions) in the Tem1-TT–treated 
group compared with TT-treated controls (Figure 4B). The reduc-
tions in both area of perfusion and blood flux in Tem1-TT–vacci-
nated tumors were statistically significant (P = 0.008 and P = 0.010, 
respectively; Figure 4B), which suggests that Tem1-TT vaccination 
disrupts the functional vasculature within the CT26 tumor.
We next assessed the apoptotic index of CT26 tumors by 
TUNEL assay. Compared with CT26 tumors from TT-immunized 
mice, cellular apoptosis increased in tumors from Tem1-TT–
immunized mice (P = 0.014; Supplemental Figure 3A). We also 
observed colocalization of these apoptotic cells with the CD31 
antigen (Supplemental Figure 3B), indicative of cell death of ECs 
of the tumor vasculature. Lastly, we also observed a reduction of 
cells positive for Ki-67, a marker for proliferating cells, within 
tumors from Tem1-TT– versus TT-immunized mice, which indi-
cates that Tem1-TT vaccination lowers the proliferative capacity 
of the tumor, a likely consequence of disruption of the tumor vas-
culature (data not shown).
Next, the microvasculature density (MVD) of the tumors was 
measured by immunohistochemical staining of CD31. CT26 
tumors from Tem1-TT–treated mice displayed reduced MVD com-
pared with TT-treated tumors (Figure 4C). In addition to fewer 
CD31+ ECs per hpf, structural disorganization of the vascula-
ture was noted: Tem1-TT–treated tumor vessels appear flattened 
with less luminal space (Figure 4C), suggestive of vessel collapse 
as well as difficulty assembling new vasculature. Lastly, we tested 
whether reduced tumor perfusion in Tem1-TT–vaccinated mice 
was associated with an increase in tumor-associated hypoxia. Using 
immunohistochemistry, an increase in carbonic anhydrase IX 
(CAIX), a cellular biomarker of hypoxia, was observed in tumors of 
Tem1-TT– versus TT-vaccinated mice (Figure 4D). Analysis by qRT-
PCR also showed an increase in Caix message levels in tumors from 
Tem1-TT–treated mice relative to controls (Figure 4D). These data 
suggest an association between reduced tumor blood perfusion 
and hypoxia in CT26 tumors from Tem1-TT–vaccinated mice.
Tem1-TT vaccination induces T cell responses against tumor-associated 
antigens as well as TEM1 antigen. Next, we tested whether immuniza-
tion against TEM1 by Tem1-TT vaccine results in epitope spread-
ing, an immunological phenomenon in which immunotherapy 
or chemotherapy kills tumor cells and induces cross-presentation 
of tumor-associated antigens followed by cross-priming (28, 29). 
Tumor antigen–specific vaccines can also induce epitope spread-
ing, inducing specificity against antigens unrelated to the original 
vaccine target (30, 31).
We hypothesized that the antivascular effects described above 
would provide a rich source of dead or dying tumor/stromal 
cells capable of supporting a corollary cross-priming event that 
would generate immune responses to antigens other than TEM1. 
We used the immunodominant AH1 (gp70423–431) peptide in the 
immunological assays. AH1 is the MHC class I–associated epi-
tope for CT26 tumor, and as such, AH1-specific CD8+ T cells 
can cure mice of established CT26 tumor (32, 33). AH1 peptide 
is derived from an endogenous retroviral gene product, gp70, 
expressed by CT26 cells (32). Splenocytes from CT26 tumor-bear-
ing BALB/c mice vaccinated with Tem1-TT exhibited a specific 
response against TEM1516–530 but not against the TEM1506–520 
control peptide, as expected, but they also exhibited a vigor-
ous response against the AH1 peptide, as measured by IFN-γ 
ELISpot (Figure 5A). Tumor-bearing mice immunized with con-
trol TT vaccine did not respond to any of these peptides (data not 
shown). As measured by IFN-γ ICS, Tem1-TT vaccine induced 
Figure 6
Wound healing is not delayed by Tem1-TT immunization. (A) Time course of wound healing. C57BL/6 mice were vaccinated 5 times with Tem1-TT 
or TT vaccine. 10 days after the final vaccination, 2 circular wounds were inflicted on the upper back of the mice. The wound area was measured 
every 2 days. Data are mean ± SD of 2 experiments (n = 10 per group for each experiment). P = 0.726, Tem1-TT vs. TT, pairwise multiple-com-
parison Tukey test. (B and C) TEM1-specific response. 20 days after the punch biopsies, mice were sacrificed to check the immune response 
against TEM1 antigen by IFN-γ ELISpot (B) and ICS (C) of bulk splenocytes (1 × 106). Statistical analyses were performed with Student’s t test.
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both CD4+ and CD8+ T cell responses against TEM1516–530, while 
the response to AH1 was restricted to CD8+ cells, as expected 
(Figure 5A). The frequency of the TEM1 CD8+ T cell response 
from Tem1-TT–vaccinated mice was inversely correlated with 
tumor volume (Figure 5A), as was the CD4+ T cell response (data 
not shown). A similar inverse correlation was found between the 
AH1-specific CD8+ T cell response from Tem1-TT–vaccinated 
mice and tumor volume (Figure 5A).
To further understand the potency of the antivascular TEM1 
response and the subsequent antitumor AH1 response, we per-
formed adoptive T cell transfer from Tem1-TT–immunized naive 
or CT26 tumor–bearing mice to recipient mice that were chal-
lenged with CT26 tumor. CD3+ T cells from Tem1-TT–immu-
nized naive and tumor-bearing donor mice both significantly 
increased the survival of recipient mice injected with CT26 
(Supplemental Figure 4, A and B). This result showed that the 
anti-TEM1 immune response generated by Tem1-TT in the non–
tumor-bearing donor mice (without concomitant cross-priming 
and epitope spreading, as in the tumor-bearing mice) was suffi-
ciently potent to control tumor growth, comparable to CD3+ cells 
adoptively transferred from Tem1-TT–immunized tumor-bearing 
mice (Supplemental Figure 4, A and B). As expected, adoptively 
transferred CD3+ cells from Tem1-TT–immunized naive mice 
exhibited a response against TEM1516–530, but not against AH1 as 
in the tumor-bearing mice.
To confirm the epitope spreading phenomenon, we analyzed 
a second tumor model, TC1, a C57BL/6 epithelial lung tumor 
cell transformed by HPV E6 and E7 viral oncogenes. E7-derived 
peptide (E749–57) is the immunodominant epitope that can cure 
mice of established tumors (34). Mice immunized with Tem1-TT 
or control vaccine were challenged with TC1, as described previ-
ously. Splenocytes from Tem1-TT–vaccinated mice displayed 
CD8+-specific immune responses against TEM1696–710 peptide (but 
not the control peptide TEM1691–705), as well as against the E749–57 
epitope (Figure 5B). As we observed in the CT26 model, the fre-
quency of both TEM1- and E7-specific CD8+ immune responses 
correlated with TC1 tumor control (Figure 5B). Thus, effective 
Tem1-TT vaccination elicited a T cell–mediated response against 
both the tumor vasculature antigen (TEM1) and also against anti-
gens expressed by the tumor cells themselves (gp70 and E7).
Tem1-TT vaccination does not affect wound healing or reproduction. 
Physiologic angiogenesis is critical for wound healing, and anti-
angiogenic agents such as bevacizumab have been associated with 
important safety concerns, including wound healing (35–37). We 
assessed whether wound repair was impaired by Tem1-TT immu-
nization in C57BL/6 mice by wounding animals on their backs 
after immunization. There was no significant difference in time to 
wound closure between Tem1-TT– and control-vaccinated groups, 
despite generation of robust anti-TEM1 responses as measured by 
IFN-γ ELISpot and ICS (Figure 6, A–C).
Reproductive organs are sites of de novo angiogenesis, with both 
the corpus luteum and placenta being heavily dependent on for-
mation of new blood vessels (38–40). Antiangiogenic compounds 
have been associated with defective luteogenesis, reproductive 
dysfunction, pregnancy loss, and teratogenesis (41–43). Previous 
studies have reported TEM1 expression in several tissues of the 
mouse embryo (22, 44). Postnatally, although TEM1 expression 
is downregulated in most organs, some expression persists in the 
renal glomerulus and in the adult uterus, where the expression 
pattern varies with the stage of the estrous cycle (45). Immunologi-
cal targeting of the vascular TEM1 antigen could therefore have 
significant side effects on the reproductive system.
To test whether Tem1-TT immunization affects various 
aspects of mouse reproduction, female mice were immunized 
with Tem1-TT or TT vaccine and then mated (see Methods). 
Tem1-TT immunization had no effect on pregnancy success 
rate (P = 0.572), time to gestation (P = 0.698), total litter size 
(P = 0.552), and pup weight at birth (P = 0.409) compared with con-
trol immunization (Figure 7A). Furthermore, there were no ana-
tomical or histological abnormalities in embryos from Tem1-TT– 
or control-immunized groups during early (E10) or late (E19) 
gestation (Figure 7B). We also assessed the potential effects of 
Tem1-TT immunization on various organs of vaccinated pregnant 
mice postpartum and found no abnormality in heart, lungs, liver, 
uterus, ovary, or placenta (Figure 7C). Similarly, organs from non-
pregnant mice, including the uterus and the renal glomeruli, had 
no abnormalities after Tem1-TT immunization. To ensure that 
pregnancy did not dampen the effectiveness of Tem1-TT vaccina-
tion, we measured TEM1-specific T cell responses (TEM1696–710) by 
IFN-γ ELISpot and ICS in the same female mice as above that were 
impregnated and gave birth, as well as in Tem1-TT–immunized 
mice that did not become pregnant after vaccination (Figure 7E 
and Supplemental Figure 5). TEM1 responses were roughly equal 
between pregnant and nonpregnant mice that were Tem1-TT 
immunized (Figure 7E). The ICS assay similarly showed that the 
TEM1 response was roughly of equal frequency between pregnant 
and nonpregnant mice and CD8+ specific (Supplemental Figure 
5), as expected with this TEM1 peptide.
Lastly, because antiangiogenic agents may disrupt luteogenesis 
(38, 46, 47), we also tested reproductive endocrine function after 
Tem1-TT vaccination in a separate independent experiment. Mice 
were vaccinated only, then had their estrous cycle synchronized 
by medroxyprogesterone, and serum levels of 17β-estradiol (E2), 
progesterone (P4), luteinizing hormone (LH), and follicle-stim-
ulating hormone (FSH) were measured longitudinally. Patterns 
of E2, P4, FSH, and LH expression were similar between TT- and 
Figure 7
Tem1-TT vaccine does not affect reproduction. C57BL/6 female mice 
were vaccinated 5 times with Tem1-TT or TT vaccine followed by mat-
ing 1 week later. (A) Tem1-TT did not alter reproduction. Vaccination 
had no effect on fertility, gestation time, number of pups, or weight 
of pups (n = 15 per group). Data are representative of 2 independent 
experiments. Statistical analyses were performed with Student’s t test. 
(B) Tem1-TT vaccine did not affect embryonic development. H&E stain-
ing of embryos of female mice vaccinated with TT and Tem1-TT showed 
no abnormalities detected for either group. (C) Tem1-TT vaccination did 
not induce tissue pathology. Histological analysis of lung, heart, liver, 
spleen, kidney, colon, ovary, uterus, and placenta from pregnant (post-
partum) and nonpregnant mice (no placenta) revealed no pathological 
effects by either vaccine. Original magnification, ×10, except spleen 
and ovary (×4). (D) Tem1-TT vaccination did not affect the estrus cycle. 
In a separate independent experiment, sera from immunized mice had 
synchronized estrus cycles and were evaluated for reproductive hor-
mones. No fluctuations were noted. (E) TEM1-specific T cell responses 
were unaltered by pregnancy. 1 × 106 splenocytes of vaccinated preg-
nant and nonpregnant mice were tested against TEM1696–710 peptide or 
control peptide (TEM1691–705) using IFN-γ ELISpot. Mice were boosted 
with a single injection of Tem1-TT or TT 45 days after the last immuni-
zation, then sacrificed 2 weeks later. There was significant recognition 
of TEM1696–710 peptide by Tem1-TT– versus TT-vaccinated splenocytes 
from both pregnant and nonpregnant mice splenocytes (n = 5).
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Tem1-TT–vaccinated groups (Figure 7D); therefore, Tem1-TT did 
not modulate hormone levels during estrus. Collectively, Tem1-TT 
vaccination appears to have no untoward effects on physiological 
processes in mice that depend on de novo angiogenesis.
Discussion
Tumor vasculature is critical for tumor growth and presents 
unique immunological epitopes, becoming an attractive target for 
therapy. Although many antiangiogenic and vascular-disrupting 
therapeutic approaches have been developed, immunotherapy 
offers the unique advantage of protective memory. Active immuni-
zation against whole tumor–derived ECs has produced encourag-
ing preclinical results, but is not practical (48–50). Development of 
active vaccination targeting vascular epitopes has been previously 
reported, but safety has not been adequately addressed (31, 51). In 
some experiments using adoptive therapy of T cells engineered to 
recognize the vascular growth factor 2 receptor, there was severe 
dose-dependent toxicity (52). Thus, identification of unique epi-
topes on the tumor vasculature that are suitable for immuno-
therapy is of high significance for the tumor immunology field. 
TEM1 is a surface protein expressed by tumor endothelial and 
endothelial progenitor cells (53) as well as pericytes and tumor-
associated fibroblasts (19, 54, 55) and is found in the vascula-
ture of tumors (4, 14, 56–61), but not in normal vessels (57, 58). 
TEM1 is implicated in vascular cell adhesion, migration, develop-
ment (62, 63), neoangiogenesis (57, 58), and tumor progression 
(20), and its overexpression is associated with poor survival (61). 
Importantly, Tem1–/– mice were previously shown to resist tumor 
growth, invasiveness, and metastasis, but were otherwise healthy 
and exhibited normal wound healing (64). Thus, knockout of 
TEM1 greatly attenuated tumor establishment and progression, 
without affecting physiologic angiogenesis. However, whether this 
null phenotype can be reproduced through therapeutic means is 
not known. We showed here for the first time that effective immu-
nization against TEM1 closely phenocopied the Tem1–/– mouse, 
severely prohibiting the establishment of tumors and inhibiting 
the progression of tumor growth without affecting reproduction 
and/or would healing.
We developed a DNA vaccine that expresses the full-length 
mouse Tem1 cDNA fused to TT adjuvant. Immunization with 
the Tem1-TT vaccine reduced tumor vasculature compared with 
mice given control vaccine, as measured by MVD, functional imag-
ing (ultrasound imaging of blood perfusion and blood flux), and 
hematocrit levels and indirectly supported by increased levels of 
CAIX in the tumor, suggestive of localized hypoxia therein. Sple-
nocytes from Tem1-TT–vaccinated mice actively secreted IFN-γ 
and lysed TEM1-expressing ECs in vitro and specifically induced 
a cellular immune response that controlled tumor progression. 
Cumulatively, these findings indicate that vaccination with Tem1-
TT specifically targets the TEM1-expressing cells of the vascular 
system and can functionally disrupt the tumor vasculature.
Breaking tolerance to TEM1 with DNA vaccine required the 
fusion of Tem1 and TT genes. TT may enhance immunogenic-
ity through several mechanisms; the whole C fragment of TT 
activates DCs to secrete cytokines involved in CD4+ T cell acti-
vation (11, 65). In addition, fragment C contains universal T 
helper epitopes (p30, p2), which are effective across different 
MHC class II haplotypes in mice and humans and elicit strong 
CD4+ responses (66). Peptides within domain 2 of fragment C are 
strong CD8+ CTL epitopes, which may compete with the fusion 
peptides. Elimination of domain 2 enhances CTL responses to 
fused peptides (67), and thus we eliminated it from our TT con-
Figure 8
Proposed mechanism of action of Tem1-TT vaccination. (i) Tem1-TT vaccine induces expansion of TEM1-specific CD8+ T cells that target the CT26 
tumor vasculature. These cytolytic effectors target and kill TEM1-expressing cells, most likely tumor-associated endothelial cells and/or pericytes. 
(ii) This event results in reduction of the tumor vasculature, inducing inflammation and tumor hypoxia, which results in localized tumor cell death. 
(iii) Dead tumor cells are scavenged by APCs, which process relevant tumor-associated antigens (TAA; e.g., AH1 antigen in CT26 tumor model). 
(iv) This cross-presentation event results in a secondary cross-priming event that expands tumor-specific cytotoxic CD8+ T cells to tumor cell–
derived epitopes. (v) Tumor-specific cytotoxic CD8+ T cells lyse and eliminate tumor cells, resulting in control of tumor growth.
Downloaded on March 20, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/67382
research article
 The Journal of Clinical Investigation   http://www.jci.org 11
transfer experiments with the CT26 model showed that Tem1-TT 
vaccination generated TEM1-specific CD3+ T cells that, on their 
own, could directly delay tumor growth and confer survival advan-
tage to mice. These data also showed that Tem1-TT vaccination 
generated a dually specific T cell response, with a primary TEM1-
specific response targeting the tumor vasculature generated by 
Tem1-TT vaccine, and a secondary response targeting the tumor 
cell–specific antigen AH1 generated by epitope spreading.
An ideal tumor vasculature antigen is one that is overexpressed 
in tumors and poorly expressed in peripheral tissues. Expression 
of TEM1 in the mouse is spatiotemporally regulated. By using a 
lacZ knockin model, Tem1 gene expression was initially detect-
able in the kidney of prenatal embryos (45). Postnatally, Tem1 
expression decreases in most organs, but persists in the renal 
glomerulus and in the adult mouse uterus. In mice immunized 
with Tem1-TT, we did not observe toxicity in association with 
angiogenic processes, such as reproduction or wound healing. 
It is perhaps surprising that the Tem1-TT vaccine could mediate 
tumor vessel destruction without causing significant toxicity dur-
ing pregnancy and wound healing. However, angiogenesis dur-
ing tumor development differs significantly from the uterine NK 
cell–driven angiogenesis seen during implantation and placenta 
development (76, 77) and from the highly organized, slow growth 
of wound healing. In addition, tissue specificity and cells involved 
in tumor vessel recruitment differ from superficial wounds, 
although many similarities exist (78).
Cumulatively, our data indicated that immunization with a 
DNA vaccine encoding Tem1-TT induces TEM1-specific cell-
mediated immune responses, disrupts the tumor vasculature, 
and controls tumor growth without affecting important normal 
physiological functions. Our preclinical data set can serve as a 
foundation for clinical studies targeting human TEM1 tumor 
vasculature antigen.
Methods
Mouse strains and cell lines. 8-week-old C57BL/6 (H-2b) and BALB/c (H-2d) mice 
were purchased from Charles River. Lung tumor cell line TC1 transformed 
by HPV E6 and E7 viral oncogenes (H-2b), lung carcinoma line LLC (H-2b), 
colon carcinoma line CT26 (H-2d), leukemia cell line MBL2 (H-2b), and EC 
lines MS1 (H-2b) and H5V (H-2b) were cultured in RPMI 1640 (Cellgro; 
catalog no. 10-104-CV) or DMEM (Cellgro; catalog no. 40-101-CV) medi-
um supplemented with 2 mM l-glutamine and 150 U/ml streptomycin 
plus 200 U/ml penicillin (Cellgro; catalog no. 30-0010CI) and 10% heat-
inactivated FBS (Gibco; catalog no. 35-010-CV).
DNA vectors and immunization procedures. The vaccine construct was gener-
ated by fusing mouse Tem1 cDNA (nt 1–2,297; aa 1–765) with the cDNA of 
the aminoterminal domain of fragment C of TT. The TT fragment DNA was 
introduced at the 3′ end of the Tem1 coding sequence, generating the plas-
mid pcDNA3.1/Tem1-TT. The codon usage-optimized cDNA of Tem1-TT 
was synthesized by oligonucleotide assembly (GeneArt; Life Technologies). 
All constructs were routinely sequenced by the DNA sequencing core facil-
ity at University of Pennsylvania, and Tem1 and TT constructs were con-
firmed with the correct sequences. DNA immunization was performed as 
described previously (79). Briefly, 50 μg plasmid in saline was injected i.m., 
and electrogene transfer was performed (2 pulses at 100 mV for 200 ms) 
immediately after injection. In Figure 3A (prophylactic setting), mice were 
euthanized when tumors reached approximately 2,000 mm3.
RNA isolation and qRT-PCR. Total RNA was isolated from 100–500 mg frozen 
organs or tumors with TRIzol reagent (Invitrogen; catalog no. 15596-018). 
After treatment with RNase-free DNase (Invitrogen; catalog no. AM2222), 
struct accordingly. In addition, we generated localized inflamma-
tion by in vivo electrogene therapy during both prime and boost 
injections. Electrogene therapy enhances responsiveness (68, 69) 
and has facilitated translation of DNA vaccines into clinical tri-
als (12, 70, 71). All of these attributes may be contributing to the 
generation of potent anti-TEM1 immune responses we observed 
with Tem1-TT immunization.
Our approach used full-length antigen rather than peptide, 
thus bypassing a major limitation of peptide-based cancer vac-
cines, namely MHC restriction. Genetic fusion of TT to the 3′ 
end of full-length antigens has been tested previously by us and 
others (13, 72). Our DNA vaccine elicited CD4+ and CD8+ anti-
TEM1 responses in the BALB/c mouse and a CD8+ response in 
the C57BL/6 mouse. Given the prime/boost approach we used, 
it is likely that the responses observed are directed against the 
immunodominant TEM1 epitopes in each mouse strain (11, 73). 
Other adjuvant formulations may identify alternative dominant 
and/or subdominant epitopes.
In previous mouse studies, DNA vaccination with the tumor-
associated antigens AH1 and E7 induced CD8+ cell–dependent 
regression of established tumors that expressed those antigens 
(33, 74). In the studies presented here, fusion of the TEM1 anti-
gen to the TT adjuvant increased the immunogenicity of the tar-
get antigen and the efficacy of tumor control. It also generated 
robust CTL activity against tumor cell proper immunodominant 
epitopes, such as AH1 and E7. This was not achieved by direct 
targeting of these antigens, but rather indirectly by targeting 
the vasculature antigen TEM1. Taken together, our data sug-
gest a model whereby Tem1-TT vaccination induces expansion 
of TEM1-specific T lymphocytes (Figure 8). These effector T cells 
target TEM1-expressing cells in the tumor vasculature, includ-
ing tumor-associated ECs and/or pericytes. This immune attack 
impairs the tumor vasculature, with increases in local tumor-
associated hypoxia and likely inflammation-related mediators, 
resulting in apoptosis of local tumor cells. These apoptotic bod-
ies are scavenged by macrophages and DCs that process and 
present additional tumor-associated antigens. This secondary 
cross-priming event then expands tumor-specific cytotoxic CD8+ 
T cells, which work hand in hand with the anti-TEM1 immune 
response to eradicate larger numbers of tumor cells, resulting in 
improved control of tumor growth. The anti-TEM1 response and 
the antitumor immune responses against AH1 and E7 signifi-
cantly correlated with control of tumor growth. Further studies 
will address the kinetics of the TEM1 and AH1 immune response. 
Our findings are consistent with the general paradigm of epitope 
spreading as a mechanism underlying superior immunotherapeu-
tic outcomes and extend this concept to include T cell specificities 
against tumor-associated vasculature antigens (75).
The results of our adoptive transfer experiments (Supplemental 
Figure 2) suggest that tumor control by Tem1-TT vaccination is 
mediated primarily by CD3+ cells, while serum (containing antibod-
ies) does not play any major therapeutic role. We did not directly 
measure anti-TEM1 antibodies potentially generated by Tem1-TT, 
and therefore cannot entirely rule out the possibility that anti-
TEM1 antibodies contribute to the observed efficacy of Tem1-TT 
vaccine in some capacity. Adoptive cell transfer also illustrated the 
effective generation of memory responses: mice challenged with 
tumor 6 months after adoptive transfer of CD8+ T cells remained 
tumor free (data not shown), which illustrated that Tem1-TT gener-
ated robust, long-lasting adaptive immune responses. The adoptive 
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sciences — Pharmingen; catalog no. 551506). The following day, strep-
tavidin-alkaline phosphatase conjugate (BD Biosciences — Pharmingen; 
catalog no. 554065) was added for 30 minutes. Plates were developed by 
adding nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate 
(Pierce), and spots were then counted using an automated ELISpot reader 
(Autoimmun Diagnostika GmbH).
ICS for IFN-γ. 5 × 106 mouse splenocytes in 1 ml RPMI with 10% FCS 
were incubated with the indicated peptides (final concentration of each 
peptide, 1 μg/ml) and 1 μg/ml brefeldin A (BD Biosciences — Pharmingen) 
at 37°C for 12–16 hours as previously described (81). Cells were washed, 
stained with surface antibodies, fixed, permeabilized, and incubated with 
FITC-labeled IFN-γ antibody (BD Biosciences — Pharmingen; catalog no. 
554411). Cells were fixed with 1% formaldehyde solution in PBS and ana-
lyzed on a FACSCanto flow cytometer using Flowjo software (Treestar).
MLPCs. MLPCs were set up with 5 × 106 splenocytes from vaccinated 
mice stimulated in vitro with 1 μg/ml specific peptide. The culture was 
incubated for 5 days in DMEM with 10% FBS at 37°C in 5% CO2.
ELISA. 105 splenocytes from MLPCs were restimulated for 24 hours in 
triplicate with an equal number of target cells, supernatants were harvested, 
and IFN-γ secretion was measured by ELISA (Biolegend). Serum from vac-
cinated mice was evaluated by ELISA to check the level of P4 (Enzo; catalog 
no. ADI-900-011), E2 (Enzo; catalog no. ADI-900-008), LH (Uscnk), and FSH 
(Uscnk). Mouse hemoglobin ELISA kit was obtained from Kamiya Biomedi-
cals. Briefly, 100 mg fresh tumor was lysed with 200 μl RIPA buffer. Mouse 
hemoglobin quantification was performed according to the manufacturer’s 
protocol with 2 μg/ml tumor lysate. Reading results were interpolated to test 
sample values from fitted calibration curve of mHgb serial dilutions. Each 
value represents the mean of triplicates from a mouse tumor. Representative 
results of 3 independent measurements are shown from 5 mice per group.
Cytotoxicity assay. Cytotoxicity was measured by 51Cr release assay. MLPCs 
were incubated with MBL2 cells, MS1 cells, or H5V cells that were unpulsed 
or pulsed with the TEM1696–710 peptide. Target cells were labeled with 100 μCi 
51Cr (Amersham) before being mixed with effector cells. Assays were per-
formed in triplicate, and supernatants were harvested to measure 51Cr 
released. Specific lysis was calculated from triplicate samples as (experi-
mental cpm – spontaneous cpm)/(maximal cpm – spontaneous cpm) and 
expressed as a percentage.
Immunohistochemical tumor analysis. CAIX, CD31, and CD3 were detected 
by immunohistochemistry in solid tumors. Tumors were embedded in 
OCT medium and immediately snap frozen in dry ice. Sections (6 μm 
thick) were stained for mouse CAIX (R&D Systems; catalog no. AF2344, 
DAB chromogen), CD31 (BD Biosciences — Pharmingen; clone 390, cata-
log no. 558737, DAB chromogen), and CD3 (BD Biosciences — Pharmin-
gen; clone 15.5-2C11, catalog no. 550275, DAB chromogen) with hema-
toxylin as a counterstain. For TUNEL assay, frozen sections (6 μm thick) 
of the OCT-embedded tissue were air dried for 30 minutes under the hood 
and fixed with 2% paraformaldehyde in PBS for 30 minutes at room tem-
perature. Each slice was treated with 100 μl of 3% H2O2-methanol solution 
for 20 minutes at room temperature and washed 3 times in PBS. To cover 
the nonspecific binding sites, each slice was treated with 10% normal goat 
serum blocking solution for 1 hour at room temperature. Tissue sections 
were incubated overnight at 4°C with rat anti-mouse CD31 primary anti-
body (1:200 dilution; BD Biosciences — Pharmingen; catalog no. 550274). 
After washing 3 times in PBS, the slices were incubated with Texas Red 
goat anti-rat IgG secondary antibody (1:500 dilution; Vector Laboratories; 
catalog no. TI-9400) at room temperature for 1 hour. To identify the apop-
totic dead cells in situ, TUNEL was performed with Cell Death Detection 
Kit (Roche Applied Science; catalog no. 11684809910) according to the 
manufacturer’s instructions. Images of the slides were taken using a Nikon 
Ti fluorescence microscope and a Leica TCS SP8 confocal microscope.
RNA was reprecipitated, quantified by spectrophotometry, and analyzed 
for RNA integrity by gel or Bioanalyzer. Total RNA was reverse transcribed 
using the Superscript First-Strand Synthesis Kit (Invitrogen; catalog 
no. 10928-042) for RT-PCR under conditions described by the supplier. 
qRT-PCR was performed with inventoried mouse Tem1 probe (ABI Biosys-
tems; catalog no. Mm00547485) as well as 18S probe as an endogenous con-
trol (4310893E-0710037). Samples for Tem1 expression in mouse organs 
were normalized using mouse liver as a calibrator. RNA isolated from 
tumor was used to set up qRT-PCR, with mouse Caix as a probe, as well 
as 18S probe as an endogenous control. To monitor TEM1 expression in 
transfected cells, CHO cells were transfected with 1 μg Tem1-TT plasmid or 
single constructs in a 6-well dish. After 48 hours of incubation, whole-cell 
lysates were harvested, and total mRNA was extracted using TRIzol. The 
Tem1 and TT RNA present in the cell lysates was detected by qRT-PCR with 
custom primers for optimized Tem1 and optimized TT, as designed by ABI 
Biosystems by PrimerExpress. Post–qRT-PCR analysis to quantitate rela-
tive gene expression was performed by the comparative Ct method (2−ΔΔCt). 
Error bars denote SD (n = 3) unless otherwise indicated.
RNA FISH. Frozen tissue was sectioned onto poly-l-lysine–coated cov-
erglasses (BD Biocoat; catalog no. 354085), fixed in formaldehyde, per-
meabilized, and stored in 70% ethanol. The single molecule RNA-FISH 
protocol was carried out as described previously (80). Samples were 
hybridized to the FISH probes overnight at 37°C in 2× SSC with 10% (v/v) 
formamide (Ambion; catalog no. AM9342) and 10% (w/v) dextran sulfate 
(Sigma-Aldrich; catalog no. D8906). For Tem1 and CD31, probe mixtures 
consisted of 48 20-mer DNA oligonucleotides (Biosearch Technologies) 
each, designed to tile their respective coding sequences, and coupled to 
Cy5 (Tem1) and Cy3 (CD31). After washing with PBS to remove unbound 
probe and storage for a few days, samples were stained for CD31 by over-
night incubation with biotin-conjugated rat anti-mouse CD31 (BD Biosci-
ences — Pharmingen; clone MEC13.3) at 4°C in PBS (1:250 dilution) and 
a 20-minute incubation with FITC-labeled streptavidin (BD Biosciences — 
Pharmingen; catalog no. 554060) at 4°C in PBS. Samples were mounted 
in a glucose oxidase–based 2× SSC antifade buffer (Sigma-Aldrich; cata-
log no. G2133) and imaged on a conventional wide-field epifluorescence 
microscope (Nikon Eclipse Ti) with a ×100 1.4 NA oil immersion objective. 
Image stacks were acquired with 0.35-μm vertical spacing and collapsed 
into single 2D images by maximum projection.
Synthetic peptides. A mouse TEM1 peptide library of 151 peptides gen-
erated as 15 mers overlapping by 10 aa was synthesized by Mimotopes 
and dissolved in DMSO at approximately 20 mg/ml. Pools, minipools, 
and individual peptides were used at 2 μg/ml. kb-restricted TEM1691–705 
peptide (ESGLAGQSQRDDRWL), TEM1696–710 peptide (GQSQRD-
DRWLLVALL), E7 peptide (RAHYNIVTF), β-gal (DAPIYTNV) and Ld-
restricted TEM1506–520 peptide (PDLPFGHKPGITSAT), TEM1516–530 
peptide (ITSATHPARSPPYQP), and AH1 peptide (SPSYVYHQF) were all 
synthesized by JPT. The 151 15-mer peptides were divided into pools A–D, 
with approximately 40 peptides each (pool D contained fewer peptides), to 
identify immunoreactive peptides (Figure 2, A and B). Once immunoreac-
tive pools were identified, peptides from pools C and D (Figure 2, C and D) 
were divided into 7 minipools of 15 mers, so each individual peptide was 
present in 2 minipools and could be identified through an experimental 
7×7 matrix design (23).
ELISpot. 96-well MAIP plates (Millipore; catalog no. N4510) were coated 
overnight with a 2.5 μg/ml solution of rat anti-mouse IFN-γ (BD Biosci-
ences — Pharmingen; catalog no. 551216). Bulk splenocytes were plated 
at 1 × 106 cells/well in triplicate and incubated for 20 hours at 37°C with 
2 μg/ml peptides. After incubation, plates were washed with PBS and 
0.05% Tween 20 (Bio-Rad; catalog no. 170-6531) and incubated overnight 
at 4°C with anti-mouse biotin-conjugated anti–IFN-γ antibody (BD Bio-
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The wound-healing assay used in this study was done according to pre-
viously described methods (85). Briefly, 7 days after the last immuniza-
tion with DNA vaccine, mice were anesthetized, hair was removed, and 
skin was cleaned with an aseptic wipe. 2 circular defects were outlined 
using a fine-tipped marking pen. The defect was created by elevating the 
skin and panniculus carnosus in the center of the outlined defect using 
forceps, followed by excision of the outlined area using microdissecting 
scissors. The wound area was sealed with Tegaderm dressing (Nexcare; 
catalog no. 55379) to prevent infection. Wound area was measured every 
day and calculated with ImageJ software. Average time to wound closure 
was monitored and considered complete when a scar was formed without 
any visible scab left.
Adoptive cell transfer. Tumor-free mice (C57BL/6 and BALB/c) and CT26 
tumor-bearing mice were vaccinated 3 times; mice were sacrificed 1 week 
after the last vaccination, and splenocytes were used to magnetically iso-
late the lymphocyte population (CD3+ T cells) (Miltenyl Biotec). Serum 
was also collected from vaccinated mice by intracardiac bleeding. Isolated 
lymphocytes and serum were injected in TC1 or CT26 tumor-bearing mice 
(challenged the day before adoptive transfer) that were sublethally irradi-
ated (4–5 Gy) 3 days before adoptive transfer (i.v. and i.p., respectively). 
Serum was administered twice weekly for a total of 6 injections to another 
group of tumor-bearing mice.
Statistics. 2-tailed Student’s t test was used to compare data sets where 
indicated. Single-step multiple-comparison Tukey test was performed 
for repeated measurements (Figure 3) at different time points. For CD3+ 
T cell quantification in tumor sections (Figure 3, B and C), statistical anal-
ysis for the indicated comparisons was performed using Student’s t test. 
Correlation between immune response by Tem1-TT treatment and tumor 
volume was analyzed with Pearson’s rank correlation test (Figure 5), 
in which negative r was generated (inverse correlation); when P values are 
below 0.050, one variable tends to decrease, while the other increases. All 
P values presented are 2-sided. The log-rank test was performed for the 
survival curves in Supplemental Figures 2 and 4. A P value less than 0.05 
was considered significant.
Study approval. All animal studies were approved by the IACUC and Uni-
versity Laboratory Animal Resources at the University of Pennsylvania. Mice 
were treated in accordance with University of Pennsylvania guidelines.
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Ultrasound analysis of tumor vasculature. Lipid-coated microspheres filled 
with gas (Definity Lantheus Medical Imaging Inc.) were used as contrast 
agent with power Doppler imaging to visualize the regions of perfusion in 
the tumor. In brief, CT26 tumor-bearing mice (tumor volume, ∼600 mm3) 
were anesthetized and injected with 0.02 ml octafluoropropane gas (Defin-
ity Lantheus Medical Imaging), and power Doppler imaging was performed 
using a broadband 7- to 15-MHz probe (HDI500 SonoCT; Philips). Power 
Doppler images were acquired at a frame rate of 0.5 Hz to minimize micro-
bubble destruction by the imaging ultrasound pulses. The Doppler signal 
from the inflowing contrast agent was visible in the images in color super-
imposed on the grayscale image of the tumor. Contrast-enhanced power 
Doppler imaging was performed as described previously (26). The power 
Doppler images at peak enhancement were analyzed to determine percent-
age area of the tumor with flow (percentage perfused area). The perfused 
tumor area for each treated group was calculated as the ratio of the area 
resolution by the contrast agent to the total tumor area in a single plane. 
Color-weighted fractional area of the colored pixels within the region of 
interest was measured as described previously (82). The color of each pixel 
in the contrast-enhanced power Doppler image measures the fractional vol-
ume of the contrast flowing through the pixel, and the color-weighted frac-
tional area (product of color level and fraction area covered by colored pix-
els) measures the contrast volume per unit area of tumor (blood flux) (83).
Histologic evaluation of embryo and tissues in vaccinated mice. Several organs 
(liver, lungs, small and large bowel, kidneys, heart, testis, brain, and spleen) 
and embryos at different time points (E10 and E19) were collected to assess 
for possible treatment toxicity. Tissues were fixed in 10% buffered formalin 
and embedded in paraffin. Histopathologic evaluation was performed on 
standard H&E sections.
Reproduction and wound-healing assay. To test whether Tem1-TT immuniza-
tion affects mouse pregnancy by interfering with prenatal angiogenic pro-
cesses, 6- to 8-week-old female mice were immunized 5 times as previously 
described (79). 1 week after the last immunization, mice were mated for 
48 hours with individually housed males. Coitus was monitored the fol-
lowing morning and confirmed by the presence of a vaginal plug. Half the 
mice were used to measure time to gestation, pup weight at birth, and total 
litter size. The other pregnant mice were used to check for gross abnormali-
ties of the embryos at E10 and E19 at the whole-animal level as well as at the 
organ level. For ELISpot and ICS (Figure 7E and Supplemental Figure 5), 
45 days after the last immunization, the pregnant mice above that gave 
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5 days. Serum was collected (3 mice per group pooled per time point) to 
check blood hormone levels.
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